5 consecutive boards Shaanxi Meibang Pharmaceutical Group (605033.SH): "One license, one product" policy has a relatively small impact on the company.

Shaanxi Meibang Pharmaceutical Group (605033.SH) announced that as of January 2, 2025, the company's stock has been hitting the daily trading limit for five consecutive trading days. The turnover rates for the recent five trading days were 2.5226%, 2.6101%, 13.6011%, 10.5012%, and 5.1101%, with trading amounts of 44.32 million, 51.27 million, 271 million, 241 million, and 132 million respectively. The trading index is higher than previous levels. The company stated that the "One Certificate, One Product" policy has had a minimal impact on the company. The company has always been in compliance with national policies, and its production and operation are currently normal with no significant changes in its main business. The external environment has not undergone any major changes. As of now, the company's controlling shareholder, actual controller, and concerted action party collectively hold 93.4 million shares of the company, accounting for 69.08% of the total share capital. The rest are publicly traded shares, with a small float, which poses a risk of irrational speculation in the secondary market. The company advises investors to be cautious of the risks in the secondary market trading, make rational decisions, and invest prudently.